New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Frontier Communications Corp (NASDAQ:FTR), MannKind Corporation (NASDAQ:MNKD), Sequenom, Inc (NASDAQ:SQNM), Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Frontier Communications Corp (NASDAQ:FTR) showed a volume of 22.16 million shares by the end of last trade whereas the average volume of the stock remained 8.80 million shares. The stock opened the session at $4.62 but then moved to $4.64. At that price, the stock showed a negative performance of -0.22%. Frontier Communications Corporation (Frontier) is a communications company providing services primarily to rural areas and small and medium-sized towns and cities in the United States. The Company offers a range of voice, data, Internet, and television services and products, some that are available a la carte, and others that are available as bundled or packaged solutions.
Will FTR Get Buyers Even After The Recent Rally? Find Out Here
MannKind Corporation (NASDAQ:MNKD) opened the session at $5.01 and closed the session at $4.99. The stock showed a negative performance of -0.40% in previous trading session. Traded with volume of 3.59 million shares in the prior session and the average volume of the stock remained 4.16 million shares. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company’s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia.
Has MNKD Found The Bottom And Ready To Gain Momentum? Find Out Here
Sequenom, Inc (NASDAQ:SQNM) opened the session at $2.48 and closed the session at $2.56. The stock showed a positive performance of 4.49% in previous trading session. Traded with volume of 1.99 million shares in the prior session and the average volume of the stock remained 3.12 million shares. The beta of the stock remained 0.40. Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications,
Why Should Investors Buy SQNM After The Recent Gain? Just Go Here and Find Out
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) the stock decreased -0.57% and finished the session at $1.73. Traded with volume of 221,824.00 shares in the prior session and the average volume of the stock remained 346,244.00 shares. The beta of the stock remained 10.78. InVivo Therapeutics Holdings Corp., formerly Design Source, Inc. is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity,
Will NVIV Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)